• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Immix Biopharma, Inc. - Common Stock (NQ:IMMX)

    11.49 +1.36 (+13.43%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 11, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,821,327
    Open 10.14
    Bid (Size) 11.11 (100)
    Ask (Size) 11.45 (700)
    Prev. Close 10.13
    Today's Range 9.920 - 11.55
    52wk Range 1.940 - 12.14
    Shares Outstanding 33,577,873
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law
    From Schall, Brown & Schwartz LLP
    Via Business Wire

    Performance

    YTD
    +111.6%
    +111.6%
    1 Month
    +9.2%
    +9.2%
    3 Month
    +7.8%
    +7.8%
    6 Month
    +70.7%
    +70.7%
    1 Year
    +395.3%
    +395.3%

    More News

    Read More
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc.
    From Holzer & Holzer
    Via GlobeNewswire
    News headline image
    Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma to Participate in Upcoming Investor Conferences
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities ↗
    Via Benzinga
    News headline image
    Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Nasdaq, S&P 500 Futures Rise Ahead Of Fed Decision This Week: Why NFLX, CFLT, BA, LLY, IMMX Are On Traders' Radar ↗
    Via Stocktwits
    Topics ETFs Economy Government
    News headline image
    Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
    From Immix Biopharma, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Immix Biopharma, Inc. - Common Stock publicly traded?
    Yes, Immix Biopharma, Inc. - Common Stock is publicly traded.
    What exchange does Immix Biopharma, Inc. - Common Stock trade on?
    Immix Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Immix Biopharma, Inc. - Common Stock?
    The ticker symbol for Immix Biopharma, Inc. - Common Stock is IMMX on the Nasdaq Stock Market
    What is the current price of Immix Biopharma, Inc. - Common Stock?
    The current price of Immix Biopharma, Inc. - Common Stock is 11.49
    When was Immix Biopharma, Inc. - Common Stock last traded?
    The last trade of Immix Biopharma, Inc. - Common Stock was at 08/11/26 04:00 PM ET
    What is the market capitalization of Immix Biopharma, Inc. - Common Stock?
    The market capitalization of Immix Biopharma, Inc. - Common Stock is 385.81M
    How many shares of Immix Biopharma, Inc. - Common Stock are outstanding?
    Immix Biopharma, Inc. - Common Stock has 386M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.